查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965942

大容量分子藥物原料藥CDMO市場－全球產業規模、佔有率、趨勢、機會與預測：按服務、來源、最終用戶、地區和競爭對手分類，2021-2031年

Large Molecule Drug Substance CDMO Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Service, By Source, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球大容量藥物原料藥成分的合約開發和生產 (CDMO) 市場預計將從 2025 年的 128.5 億美元成長到 2031 年的 222.8 億美元，複合年成長率為 9.61%。

該行業的公司為單株抗體和重組蛋白等生物原料藥的研發和商業化生產提供關鍵服務。生物製藥供應鏈日益複雜，以及建立內部細胞培養設施所需的大量資金，迫使企業依賴擁有專業技術和營運能力的外部合作夥伴，推動了該產業的成長。

市場概覽
預測期 2027-2031
市場規模：2025年 128.5億美元
市場規模：2031年 222.8億美元
複合年成長率：2026-2031年 9.61%
成長最快的細分市場 契約製造
最大的市場 北美洲

由於生物製藥公司日益重視核心研發活動而非生產基礎設施投資，市場前景依然樂觀。歐洲製藥工業協會聯合會（EFPIA）預測，到2024年，腫瘤研究將佔所有臨床試驗的約29%，凸顯了對專業生物製藥生產能力的強勁需求，以支持這項創新研發管線。然而，不斷變化的監管環境給該領域的擴張帶來了重大障礙，因為表徵複雜大分子的全球標準各不相同，需要進行成本高昂的營運調整才能合規，這可能會延遲市場准入。

市場促進因素

全球對生物製藥和生物相似藥的需求不斷成長，成為市場成長的主要催化劑，促使製藥研發公司儘早鎖定大規模生產能力。隨著單株抗體等高劑量療法的商業性需求增加，創新者必須確保充足的產能，以最大限度地降低供應鏈風險，並確保患者能夠持續獲得治療。近期的幾項重大合約也印證了這種確保專業生產線的壓力。三星生物製劑在2024年7月提交的監管文件中披露，該公司已與一家美國製藥公司簽訂了一份價值約10.6億美元的契約，這表明當前外包需求規模巨大。

同時，生物製藥公司正策略性地轉向資產精簡模式和成本效益，以減少內部基礎設施的資本支出。開發大規模生物反應器產能所帶來的巨大財務負擔和維護成本，促使企業越來越依賴外部合作夥伴，而這些合作夥伴也積極擴大營運規模，以滿足多元化的產品線需求。富士軟片迪奧辛斯生技公司（ Fujifilm Diosynth Biotechnologies）在2024年4月的新聞稿中宣布，將追加12億美元投資，用於擴建其位於北卡羅來納州的大型細胞培養設施，以直接應對產能需求。此次整合將使市場領導能夠在支持產業創新的同時實現財務繁榮。據龍沙（Lonza）稱，其2024年上半年的銷售額達到31億瑞士法郎，顯示這家成熟的契約製造擁有永續的收入來源。

市場挑戰

全球聚合物類藥物原料藥機構（CDMO）市場的成長受到不斷變化的監管環境以及適應不同全球標準的必要性的顯著阻礙。由於聚合物類生物製藥的結構非常複雜，不同司法管轄區的監管機構通常會要求進行各自獨特的表徵測試和生產控制。這種缺乏統一性迫使CDMO公司實施冗餘的測試通訊協定，並為每個市場維護不同的品管體系，從而顯著增加了營運成本，並限制了生產流程的全球標準化。因此，工廠產能下降，原本用於產能擴張的資金也被挪用。

監管瓶頸嚴重阻礙因素了產業成長，尤其是在大量治療藥物需要研發支援的情況下。根據美國藥品製造商協會（PhRMA）預測，到2024年，全球將有超過8,000種藥物處於臨床研發階段。如此龐大的研發管線迫使合約研發生產力機構（CDMO）加速生產進度，而因應分散的合規要求又會延緩這些產品的上市。因此，跨國快速擴張業務的困難限制了CDMO的獲利能力，並減緩了整個產業的成長動能。

市場趨勢

抗體藥物複合體（ADC）產能的擴張正在從根本上改變這一領域。合約研發生產機構（CDMO）正投入大量資金以滿足市場對這些複雜高效療法的激增需求。 ADC的生產需要高度專業化的生物安全防護設施和偶聯技術的專業知識，這迫使製藥研發公司將這些技術任務外包給擁有成熟生物偶聯設施的合作夥伴。對專業技術的強勁需求也反映在主要產業參與者的財務表現上。根據無錫西得生物科技有限公司於2025年3月發布的《2024會計年度財務報告》，該公司營收年增90.8%至40.5億元人民幣，主要得益於ADC及各類生物偶聯物相關客戶計劃的顯著成長。

同時，人工智慧數位雙胞胎在製程開發的應用，正以前所未有的效率和預測控制能力，徹底改變醫藥原料藥的生產方式。生物製藥公司正日益採用這些數位化工具來模擬實驗條件、最佳化細胞培養參數，並顯著縮短從實驗室到商業化生產所需的時間。這種向數據驅動型製造的轉變正以驚人的速度發展。根據Benchling發布的2024年11月《生物製藥技術趨勢報告》，55%已應用人工智慧的機構正將該技術專門用於製程開發功能，例如細胞株開發數位雙胞胎建模，以加速其營運流程。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：大型藥品原料藥和原料藥的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按服務類型（契約製造、合約開發）
    • 依來源（哺乳動物來源、微生物來源、其他）
    • 依最終用戶（生技公司、合約研究機構等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美大規模分子藥物原料藥與原料藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲大規模分子藥物原料藥的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區大型分子藥物原料藥（CDMO）的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲大規模分子藥物原料藥和合約研發生產機構的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲大規模分子藥物原料藥和原料藥生產機構的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：大規模分子藥物原料藥和原料藥的全球市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eurofins Scientific（Ireland）Limited
  • WuXi Biologics Co., Ltd.
  • Samsung Biologics Co Ltd
  • Catalent, Inc.
  • Rentschler Biopharma SE
  • AGC Biologics GmbH（AGC Inc. Group）
  • Recipharm AB
  • Siegfried Holding AG
  • Boehringer Ingelheim International GmbH
  • FUJIFILM Diosynth Biotechnologies USA, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23848

The Global Large Molecule Drug Substance CDMO Market is projected to expand from USD 12.85 Billion in 2025 to USD 22.28 Billion by 2031, registering a CAGR of 9.61%. Organizations in this sector deliver essential services for the development and commercial production of biologic bulk drug substances, such as monoclonal antibodies and recombinant proteins. This industry growth is driven by the increasing complexity of biopharmaceutical supply chains and the substantial capital required to establish internal cell culture facilities, which compels companies to rely on external partners for their specialized technical competencies and operational capacity.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.85 Billion
Market Size 2031USD 22.28 Billion
CAGR 2026-20319.61%
Fastest Growing SegmentContract Manufacturing
Largest MarketNorth America

The market outlook remains favorable as biopharmaceutical firms increasingly prioritize core research activities rather than investing in manufacturing infrastructure. According to 'EFPIA', in '2024', oncology-focused studies comprised nearly 29% of all clinical trials, highlighting the robust demand for specialized biologic manufacturing capabilities to sustain this innovation pipeline. However, the sector's expansion faces significant hurdles due to the evolving regulatory landscape, as adhering to divergent global standards for characterizing complex large molecules can require expensive operational adjustments and delay market entry.

Market Driver

The rising global demand for biologics and biosimilars acts as a major catalyst for market growth, prompting pharmaceutical developers to secure large-scale manufacturing slots well ahead of time. As commercial requirements for high-volume therapeutics like monoclonal antibodies increase, innovators are forced to reserve substantial capacity to minimize supply chain risks and guarantee uninterrupted patient access. This pressure to lock in specialized production lines is evident in recent major agreements; according to Samsung Biologics, July 2024, in a 'regulatory filing', the company secured a contract worth approximately $1.06 billion with a United States-based pharmaceutical company, demonstrating the massive scale of current outsourcing needs.

Simultaneously, a strategic shift toward asset-light models and cost efficiency encourages biopharmaceutical firms to reduce capital expenditures on internal infrastructure. Developing large-scale bioreactor capacity involves immense financial overhead and maintenance, leading to a reliance on external partners who continue to aggressively expand their operational footprint to accommodate diverse pipelines. According to Fujifilm Diosynth Biotechnologies, April 2024, in a 'press release', the organization announced an additional investment of $1.2 billion to expand its large-scale cell culture facility in North Carolina, directly addressing these capacity needs. This consolidation allows market leaders to thrive financially while supporting industry innovation; according to Lonza, in 2024, the entity reported sales of CHF 3.1 billion for the first half of the year, reflecting the sustained revenue streams for established contract manufacturers.

Market Challenge

The growth of the Global Large Molecule Drug Substance CDMO Market is significantly hindered by the evolving regulatory landscape and the necessity to comply with divergent global standards. Since large molecule biologics possess high structural complexity, regulatory agencies across different jurisdictions often mandate unique characterization studies and manufacturing controls. This lack of harmonization compels CDMOs to implement redundant testing protocols and maintain distinct quality management systems for separate markets, which drastically increases operational overhead and limits the ability to standardize production processes globally, thereby reducing facility throughput and diverting capital from capacity expansions.

This regulatory bottleneck acts as a substantial constraint on growth, particularly given the massive volume of therapeutics requiring development support. According to 'PhRMA', in '2024', there were more than 8,000 medicines in clinical development globally. This extensive pipeline places immense pressure on CDMOs to accelerate manufacturing timelines; however, the friction caused by navigating fragmented compliance requirements delays market entry for these products. Consequently, the inability to swiftly scale operations across international borders restricts the revenue potential of CDMOs and slows the overall momentum of the sector.

Market Trends

The expansion of manufacturing capabilities for Antibody-Drug Conjugates (ADCs) is fundamentally reshaping the sector as CDMOs invest heavily to meet the surging demand for these complex, high-potency therapeutics. Producing ADCs requires highly specialized containment infrastructure and expertise in conjugation technologies, compelling pharmaceutical developers to outsource these technical operations to partners with established bio-conjugation suites. This intense demand for specialized capacity is reflected in the financial performance of key industry players; according to WuXi XDC, March 2025, in the 'Annual Results for 2024', the company reported a revenue increase of 90.8% year-on-year to RMB 4.05 billion, driven primarily by a significant spike in customer projects for ADCs and broader bioconjugates.

Concurrently, the integration of artificial intelligence and digital twins in process development is transforming how drug substances are manufactured by offering unprecedented levels of efficiency and predictive control. Biopharmaceutical companies are increasingly adopting these digital tools to simulate experimental conditions, optimize cell culture parameters, and drastically reduce the time required to scale up production from the laboratory to commercial facilities. This shift towards data-driven manufacturing is gaining substantial traction; according to Benchling, November 2024, in the '2024 State of Tech in Biopharma Report', 55% of organizations that have adopted AI have implemented the technology specifically within process development functions, such as cell line development and digital twin modeling, to accelerate their operational workflows.

Key Market Players

  • Eurofins Scientific (Ireland) Limited
  • WuXi Biologics Co., Ltd.
  • Samsung Biologics Co Ltd
  • Catalent, Inc.
  • Rentschler Biopharma SE
  • AGC Biologics GmbH (AGC Inc. Group)
  • Recipharm AB
  • Siegfried Holding AG
  • Boehringer Ingelheim International GmbH
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

Report Scope

In this report, the Global Large Molecule Drug Substance CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Large Molecule Drug Substance CDMO Market, By Service

  • Contract Manufacturing
  • Contract Development

Large Molecule Drug Substance CDMO Market, By Source

  • Mammalian
  • Microbial
  • Others

Large Molecule Drug Substance CDMO Market, By End User

  • Biotech Companies
  • CRO
  • Others

Large Molecule Drug Substance CDMO Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Large Molecule Drug Substance CDMO Market.

Available Customizations:

Global Large Molecule Drug Substance CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Large Molecule Drug Substance CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Service (Contract Manufacturing, Contract Development)
    • 5.2.2. By Source (Mammalian, Microbial, Others)
    • 5.2.3. By End User (Biotech Companies, CRO, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Large Molecule Drug Substance CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Service
    • 6.2.2. By Source
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Large Molecule Drug Substance CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Service
        • 6.3.1.2.2. By Source
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Large Molecule Drug Substance CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Service
        • 6.3.2.2.2. By Source
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Large Molecule Drug Substance CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Service
        • 6.3.3.2.2. By Source
        • 6.3.3.2.3. By End User

7. Europe Large Molecule Drug Substance CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Service
    • 7.2.2. By Source
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Large Molecule Drug Substance CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Service
        • 7.3.1.2.2. By Source
        • 7.3.1.2.3. By End User
    • 7.3.2. France Large Molecule Drug Substance CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Service
        • 7.3.2.2.2. By Source
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Large Molecule Drug Substance CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Service
        • 7.3.3.2.2. By Source
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Large Molecule Drug Substance CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Service
        • 7.3.4.2.2. By Source
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Large Molecule Drug Substance CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Service
        • 7.3.5.2.2. By Source
        • 7.3.5.2.3. By End User

8. Asia Pacific Large Molecule Drug Substance CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Service
    • 8.2.2. By Source
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Large Molecule Drug Substance CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Service
        • 8.3.1.2.2. By Source
        • 8.3.1.2.3. By End User
    • 8.3.2. India Large Molecule Drug Substance CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Service
        • 8.3.2.2.2. By Source
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Large Molecule Drug Substance CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Service
        • 8.3.3.2.2. By Source
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Large Molecule Drug Substance CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Service
        • 8.3.4.2.2. By Source
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Large Molecule Drug Substance CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Service
        • 8.3.5.2.2. By Source
        • 8.3.5.2.3. By End User

9. Middle East & Africa Large Molecule Drug Substance CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Service
    • 9.2.2. By Source
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Large Molecule Drug Substance CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Service
        • 9.3.1.2.2. By Source
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Large Molecule Drug Substance CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Service
        • 9.3.2.2.2. By Source
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Large Molecule Drug Substance CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Service
        • 9.3.3.2.2. By Source
        • 9.3.3.2.3. By End User

10. South America Large Molecule Drug Substance CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Service
    • 10.2.2. By Source
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Large Molecule Drug Substance CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Service
        • 10.3.1.2.2. By Source
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Large Molecule Drug Substance CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Service
        • 10.3.2.2.2. By Source
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Large Molecule Drug Substance CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Service
        • 10.3.3.2.2. By Source
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Large Molecule Drug Substance CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eurofins Scientific (Ireland) Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. WuXi Biologics Co., Ltd.
  • 15.3. Samsung Biologics Co Ltd
  • 15.4. Catalent, Inc.
  • 15.5. Rentschler Biopharma SE
  • 15.6. AGC Biologics GmbH (AGC Inc. Group)
  • 15.7. Recipharm AB
  • 15.8. Siegfried Holding AG
  • 15.9. Boehringer Ingelheim International GmbH
  • 15.10. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer